About: Icariin promotes osteogenic differentiation of BMSCs by upregulating BMAL1 expression via BMP signaling

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Icariin promotes osteogenic differentiation of BMSCs by upregulating BMAL1 expression via BMP signaling Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Icariin promotes osteogenic differentiation of BMSCs by upregulating BMAL1 expression via BMP signaling
Creator	Wang, Zheng Wang, Xiang Li, Xiang Hu, Yun Huang, Zengfa Li, Zuoqin Wei, Hui Xiao, Jianwei Xie, Yuanliang Zhang, Shutong
source	Medline; PMC
abstract	Increasing research has demonstrated that expression of brain and muscle ARNT-like 1 (BMAL1) and other circadian clock genes can be regulated by drugs and toxicants. We previously demonstrated that icariin, extracted from Herba Epimedii, sromotes osteogenic differentiation. However, the mechanism underlying the association between icariin and BMAL1 in osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) remains unclear. The present study was designed with an aim to clarify the association between icariin and BMAL1 in osteogenic differentiation of BMSCs. The Cell Counting Kit-8 assay was used to evaluate cell proliferation. The expression of bone morphogenetic protein 2 (BMP2), RUNX family transcription factor 2 (RUNX2), alkaline phosphatase (ALP), osteocalcin (OC) and BMAL1 in BMSCs was evaluated by reverse transcription-quantitative PCR and western blotting. ALP and Alizarin red S (ARS) staining were also performed. Icariin promoted BMSC proliferation, and upregulated expression of osteogenic genes and BMAL1. In addition, expression of the osteogenic genes BMP2, RUNX2, ALP and OC were upregulated by BMAL1 overexpression. Furthermore, we confirmed that BMAL1 deficiency suppressed osteogenic differentiation in BMSCs. Finally, ARS staining of BMAL1(−/−) BMSCs revealed that BMAL1 was an essential intermediary in matrix mineralization during osteogenic differentiation. In conclusion, these results demonstrated that icariin promoted osteogenic differentiation through BMAL1-BMP2 signaling in BMSCs. The present study thus described a novel target of icariin that has potential applications in the treatment of osteogenic disorders.
has issue date	2020-01-20(xsd:dateTime)
bibo:doi	10.3892/mmr.2020.10954
bibo:pmid	32016461
has license	cc-by-nc-nd
sha1sum (hex)	9c4444ada7a386ec68c8180c998e0b2ec44824d8
schema:url	https://doi.org/10.3892/mmr.2020.10954
resource representing a document's title	Icariin promotes osteogenic differentiation of BMSCs by upregulating BMAL1 expression via BMP signaling
has PubMed Central identifier	PMC7002972
has PubMed identifier	32016461
schema:publication	Mol Med Rep
resource representing a document's body	covid:9c4444ada7a386ec68c8180c998e0b2ec44824d8#body_text
is schema:about of	named entity 'DIFFERENTIATION' named entity 'ICARIIN' named entity 'TREATMENT' named entity 'SIGNALING' named entity 'INTERMEDIARY' named entity 'INCREASING' named entity 'STUDY' named entity 'OSTEOCALCIN' named entity 'GENES' named entity 'KIT' named entity 'PROLIFERATION' named entity 'OSTEOGENIC' named entity 'DESCRIBED' named entity 'QUANTITATIVE PCR' named entity 'STAINING' named entity 'THE CELL' named entity 'BMAL1' named entity 'BMP SIGNALING' named entity 'CELL COUNTING' named entity 'RUNX FAMILY TRANSCRIPTION FACTOR 2' named entity 'ESSENTIAL' named entity 'DIFFERENTIATION' named entity 'ASSAY' named entity 'REVERSE TRANSCRIPTION' named entity 'APPLICATIONS' named entity 'NOVEL' named entity 'MECHANISM' named entity 'DERIVED' named entity 'TARGET' named entity 'RESULTS' named entity 'MATRIX' named entity 'POTENTIAL' named entity 'PERFORMED' named entity 'AIM' named entity 'REGULATED' named entity 'RESEARCH' named entity 'WESTERN BLOTTING' named entity 'BONE MARROW' named entity 'EXTRACTED' named entity 'SUPPRESSED' named entity 'DEFICIENCY' named entity 'ADDITION' named entity 'CLARIFY' named entity 'BONE MORPHOGENETIC PROTEIN 2' named entity 'BMSC' named entity 'UNCLEAR' named entity 'MESENCHYMAL STEM CELLS' named entity 'CONCLUSION' named entity 'UPREGULATED EXPRESSION' named entity 'PREVIOUSLY' named entity 'DRUGS' named entity 'CELL PROLIFERATION' named entity 'ASSOCIATION' named entity 'OSTEOGENIC' named entity 'EXPRESSION' named entity 'PRESENT' named entity 'RUNX2' named entity 'DEMONSTRATED' named entity 'MINERALIZATION' named entity 'BMAL1' named entity 'EPIMEDII' named entity 'ALIZARIN RED S' named entity 'ALP' named entity 'EVALUATE' named entity 'TOXICANTS' named entity 'CONFIRMED' named entity 'ARS' named entity 'BRAIN AND MUSCLE ARNT-LIKE 1' named entity 'EXPRESSION' named entity 'REVEALED' named entity 'BMP2' named entity 'USED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software